Navigation Links
Laureate Biopharma Names James D. Utterback to Board of Directors
Date:4/3/2012

PRINCETON, N.J., April 3, 2012 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc. a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of James D. Utterback to the company's Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )

"Jim is an invaluable addition to our board, and we are fortunate to have access to his deep industry knowledge," said Michael A. Griffith, Chief Executive Officer.

"Jim has more than 30 years of leadership experience building successful startups and public organizations in healthcare software, products and services globally. He has consistently innovated new approaches to growth and his customer-driven business philosophies complement Laureate's quality-focused right-first-time model."

Mr. Utterback most recently served as President, Chief Executive Officer and Board Member of M2Gen, part of the Moffitt Cancer Center in Tampa, Florida, and the third largest oncology academic medical research center in the U.S. He is Founder and Chairman of RxCeL Partners LLC, a healthcare consulting firm based in Philadelphia and Tampa. Mr. Utterback also held positions as Chief Executive Officer of SCIREX Corporation (now Premier Research), and President of the Pharmaceutical Division of Vivo Metrics, a global leader in ambulatory data collection. Earlier in his career, he was a Corporate Officer at Sanofi (then RPR) in Paris, France, and at Covance in Princeton, NJ. Mr. Utterback started his career at GE's Medical Systems Division. He earned a Master of Science in Industrial Psychology from Virginia Polytechnic Institute, and a Bachelor of Science in Psychology/Economics from Washington & Lee University.

About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981, and is a portfolio company of Saints Capital, LLC. For more information related to Laureate Biopharma's capabilities and ongoing improvements, please visit www.LBioS.com

About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and, in special situations, in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367, or info@LBioS.com or visit www.LBioS.com


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Pharma to Add More Manufacturing Capacity
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
6. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
7. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
8. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
9. Laureate Pharma Elects New Board Member
10. Thomson Reuters Predicts Nobel Laureates
11. Laureate Pharma Welcomes Three New Members to Business Development Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  An international team ... Medicine and St. Boniface Hospital Albrechtsen Research Centre/University ... neuropathy, an unmet health need affecting nearly one ... of Clinical Investigation, their results identify small molecule ... and reverse neuronal injury in animal models of ...
(Date:1/17/2017)... Noom Inc. , the leader ... offer fully Spanish behavior change programs that address ... prevention and healthy weight management programs  have ... interventions among Hispanic Americans who are at increased ... database, program-specific curriculum content and program features are ...
(Date:1/17/2017)... Thornton Cleveleys, UK (PRWEB) , ... ... ... clinical results presented by surgeons at the 2016 annual meeting of the ... and beneficial clinical outcomes, for patients in the majority of cases, when ...
(Date:1/17/2017)... and Liege, Belgium (PRWEB) , ... January 17, ... ... solutions for sample preparation and epigenetics research, recently announced a collaboration with the ... a high-sensitivity DNA amplification method for library preparation, following the company’s successful launch ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
Breaking Biology News(10 mins):